Latest BioArctic News & Updates

See the latest news and media coverage for BioArctic. We track all announcements, press releases, and industry mentions in real time, all in one place.

BioArctic

Research-oriented biopharma company for neurodegenerative diseases

bioarctic.com

Headquarters: Stockholm, Sweden
Founded year: 2003
Company type: Public company
Number of employees: 150–200
Industry: Pharmaceuticals

Last updated Today

Latest news about BioArctic

In short: BioArctic reported record profits for 2025 and signed a major $800 million Alzheimer's research deal with Eli Lilly.

Company announcements

August 24 BioArctic

BioArctic announces Leqembi Iqlik US initiation treatment launch

The subcutaneous autoinjector enables convenient at-home administration, reducing clinic visits and healthcare resource utilization for early Alzheimer’s patients.

July 29 BioArctic

BioArctic reports Leqembi sales of 29.3 billion yen in Q2 2026

Royalties to BioArctic reached SEK 179 million, up 10% year-over-year. Excluding a stockpiling effect, growth was 43%.

July 13 BioArctic

BioArctic's partner Eisai receives FDA approval for Leqembi Iqlik

The once-weekly subcutaneous injection offers at-home dosing from initiation, with launch planned for late August 2026.

July 12 BioArctic

BioArctic presents new Leqembi SC autoinjector data at AAIC 2026

The subcutaneous formulation shows similar efficacy and safety to IV formulation in early Alzheimer's disease.

Media coverage

Yesterday Financial Times

Leqembi® Pen subcutaneous formulation approved in Japan

BioArctic AB (publ)'s (NASDAQ STOCKHOLM: BIOA B) partner Eisai announced today that the subcutaneous autoinjector formulation of Leqembi (known as Leqembi Pen in Japan) has...

August 31 BioSpace

Final CDA-AMC Recommendation Brings Canadians with Early-Stage Alzheimer's Disease One Step Closer to Accessing LEQEMBI® (lecanemab) - BioSpace

Since 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study...

August 26 Yahoo Finance

Eli Lilly (LLY) Adds Alzheimer’s Research Deal As Obesity Cost Data Builds

Eli Lilly (NYSE:LLY) agreed a new research and collaboration deal with BioArctic that applies BioArctic's BrainTransporter technology to a potential Alzheimer's treatment. The BioArctic agreement...

August 26 BioSpace

LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China - BioSpace

The First and Only Anti-Amyloid Therapy in China that Enables At-Home Administration for Alzheimer’s Disease, a Progressive Neurodegenerative Disease · TOKYO and CAMBRIDGE, Mass., Sept...

Never miss news about BioArctic

Track BioArctic and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

BioArctic competitors & trending companies

Browse news for competitors to BioArctic and other trending companies.